<DOC>
	<DOCNO>NCT01847092</DOCNO>
	<brief_summary>The purpose study determine study drug safe , tolerable active reduce albuminuria patient Chronic Kidney Disease Type 2 Diabetes .</brief_summary>
	<brief_title>A Study CKD Patients With Type 2 Diabetes Mellitus Albuminuria</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Albuminuria</mesh_term>
	<criteria>Males female age 18 80 year , inclusive . Body mass index 18 45 kg/m2 , inclusive . Type 2 diabetes mellitus receive ≥1 glucose lower medication least 3 month prior randomization Stage 3 CKD MSSBP ≥130 mmHg Urinary albumin : mean UACR ≥ 200 mg/g Urinary albumin : UACR &gt; 3500 mg/g History renal transplant MSSBP &gt; 180 mmHg MSDBP &gt; 120 mmHg two occasion screen runin period History inflammatory bowel disease diarrhea predominant irritable bowel syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>albuminuria</keyword>
</DOC>